ACCELERATING THE GLOBAL RESPONSE TO ANTIMICROBIAL RESISTANCE
Celebration of New Funding
CARB-X strengthens existing partnerships and welcomes new donors
IN 2023, FOUR FUNDERS ANNOUNCED SUPPORT FOR CARB-X.

“There are more and more antibiotic-resistant bacteria worldwide, some of which are resistant to a number of antibiotics. This is why we urgently need new approaches for the prevention, diagnosis and treatment of these superbugs, which are becoming increasingly dangerous to humans. Therefore, the Federal Research Ministry has been supporting the international CARB-X partnership since 2018.”

Through its Global AMR Innovation Fund (GAMRIF), the UK government committed up to £24 MILLION to CARB-X over the next four years.

“AMR threatens modern medical systems for current and future generations. I am proud that CARB-X’s global partnership and commitment to cutting-edge innovation, equitable global access, and sustainable stewardship will bring exciting new treatments, preventative and diagnostics to those across the world who most need them.”

The Public Health Agency of Canada announced an investment of CAD $6.3 MILLION to CARB-X over the next two years.

“The Government of Canada is proud to support CARB-X in its innovative efforts to combat antimicrobial resistance (AMR). This investment will help strengthen the research and development space in Canada and contribute to global AMR innovation by strengthening the discovery and development for new antimicrobial drugs. Continued collaborative efforts such as this are crucial and Canada is committed to working with its global partners to make tangible progress on AMR.”

The Honourable Mark Holland, Minister of Health, Government of Canada

“Like CARB-X, the Novo Nordisk Foundation is committed to driving innovation in the fight against drug-resistant infections. By partnering, we can help ensure that the best research gets translated into effective, scalable and affordable medical interventions that can help end this growing pandemic.”

The Novo Nordisk Foundation committed up to USD $25 MILLION to CARB-X for three years.

“Like CARB-X, the Novo Nordisk Foundation is committed to driving innovation in the fight against drug-resistant infections. By partnering, we can help ensure that the best research gets translated into effective, scalable and affordable medical interventions that can help end this growing pandemic.”

The Novo Nordisk Foundation committed up to USD $25 MILLION to CARB-X for three years.

At a time when more than one million people die every year from drug-resistant bacterial infections, CARB-X drives innovation to save lives.

This year marks significant milestones in our journey with the addition of two new funders, the completion of three funding rounds, and a refresh of our R&D strategy.

We are thankful to the German and UK governments who have renewed their multi-year grants to CARB-X, and we are proud that the Canadian government and the Novo Nordisk Foundation have decided to join our initiative as its newest funders. Together with the US government, Wellcome and the Gates Foundation, these partners offer crucial resources to accelerate products aimed at preventing, diagnosing, and treating drug-resistant infections.

We are grateful to the G7 and G20 members for highlighting the importance of our work. In June, the G7 Health Ministers welcomed R&D on novel antimicrobials through our international initiative. We are encouraged by this widespread support and hope. Together, we are making a difference.

We look forward to engaging with more government partners to strengthen our collective response to antimicrobial resistance (AMR).

During the 2022-2023 funding rounds, CARB-X received 237 expressions of interest from around the world. They are developing oral therapeutics, vaccines for neonatal sepsis, and gonorrhea products. 91% come from micro to medium companies and academic institutions. This shows that small teams continue to lead antibacterial R&D, and this vulnerable ecosystem needs our assistance.

In the second half of the year, we embarked on a strategic review of our R&D priorities to align with the most burdensome infections worldwide. The review is a commitment to action, so our investments can make the most significant impact.

With gratitude to our partners for their support and shared vision of success, we move forward with determination and hope. Together, we are making a difference.

Kevin Outterson, Esq.
Executive Director, CARB-X

Erin Duffy, Ph.D.
Chief of Research and Development, CARB-X

Kevin Outterson, J.D., LL.M.
Executive Director, CARB-X
**Portfolio Strategy Review Results**

**IN THE SECOND HALF OF 2023, CARB-X CONDUCTED A REFRESH OF THE INITIAL 2020 PORTFOLIO STRATEGY REVIEW, INTENDED TO:**

- augment our advisory pool to better represent our role as a global funder and supporter of R&D to prevent, diagnose and treat bacterial infections;
- update external stakeholder views of: highest-need syndromes, pathogens that cause them, modalities that are best suited for the job, and performance characteristics that clinicians and patients need;
- analyze overlap (and gaps) with downstream-funder priorities; and
- prioritize recommended areas of focus for: refueling existing portfolio and shaping new funding calls.

**THE FORMAT OF THE REVIEW INCLUDED TWO COMPONENTS:**

- an online survey, which focused on syndromes, pathogens, modalities and performance characteristics; and
- a virtual panel discussion for each pillar (diagnostics, prevention and therapeutics).

In both cases, questions were included to underscore where there were similarities or areas of significant differences when considering priorities for High-Income Countries (HICs) and Low- and Middle-Income Countries (LMICs).

Where diagnostics are concerned, the outcomes were very consistent with the prioritization set in the 2020 Review and included bloodstream infections (BSI) direct from whole blood, sexually-transmitted infections (STIs), enteric infections (S. typhi) and lower-respiratory tract infections (LRTIs). Additionally, the top priorities were the same, irrespective of World Bank economic categorization.

**Our portfolio strategy review called upon advisors from around the world, as soon below:**

- With antibiotics, we still need rapid-triage tests, which rule-in a bacterial infection and rule-out other syndromes—turnaround time and sensitivity/specificity are critical.
- Diagnostics for neonatal sepsis, specifically, are lacking. Here, critical is the sample volume. In this category, rapid-triage, bacterial identification and rapid susceptibility testing are sought. This aligns well with the 2022-2023 omnibus solicitation for vaccines for neonatal sepsis.
- Where STIs are concerned, through the 2022-2023 omnibus solicitation CARB-X augmented the portfolio such that we are accelerating projects covering several levels of the healthcare delivery system. The recommendation is to invest in advancement rather than seek more projects.
- With enteric infections, diagnostics are desired. Here, speed and cost are significant drivers. The antigen/antibody combination is important.
- There was no overwhelming feeling that we need diagnostics for LRTIs. Here, the critical work seems to be around identifying proper sample types, particularly to distinguish between colonization and infection. Because so many of our therapeutic programs focus on LRTIs, this diagnostic priority aligns well.

**WHERE PREVENTION IS CONCERNED, THE TOP FOUR SYNDROMES AND SOUGHT-AFTER MODALITIES, ACROSS ALL REVIEWERS WERE:**

<table>
<thead>
<tr>
<th>Pathogen</th>
<th>Syndrome</th>
<th>Modality</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neisseria meningitidis, 3rd gen ceph-R and/or FQ-R</td>
<td>Gonorrhea</td>
<td>Vaccines</td>
</tr>
<tr>
<td>Staphylococcus epidermidis, FQ-R</td>
<td>Diarrhea</td>
<td>Vaccines</td>
</tr>
<tr>
<td>Klebsiella pneumonia, 3rd gen ceph-R</td>
<td>Pneumonia</td>
<td>Other Prevention</td>
</tr>
<tr>
<td>Staphylococcus aureus, MRSA, VRE</td>
<td>Invasive</td>
<td>Other Prevention</td>
</tr>
</tbody>
</table>

**IMPORTANT POINTS FROM THE DIAGNOSTIC PANEL DISCUSSION:**

- Where N. gonorrhoea is concerned, it was recognized that CARB-X now has 3 vaccine programs in the area, at several stages of preclinical development. At this time, this was deprioritized as a high need for additional portfolio investments.
- A focus on F. tularensis is important for LMICs but not for HICs, where only special populations with co-morbidities are affected.
- When discussing S. aureus, what rose as priorities were vaccines for pathogens that cause invasive disease. In this light, and owing to the many failures in preclinical and clinical development, preventative from non-vaccine and non-monoclonal antibody modalities were desired, for disseminated disease caused by both S. aureus and E. coii.

**KEY POINTS FROM THE THERAPEUTICS PANEL DISCUSSION:**

- The emphasis was on the need for therapeutics—particularly those with properties that allow development of an oral formulation—for serious infections caused by Gram-negative organisms.
- A high preference for direct-acting, small-molecule therapeutics (encourages development of non-traditional). Here, speed and not necessarily require a new mechanism of action or a new chemical class.
- Developers should engage clinical-trial networks in regions where drug-resistant pathogens may be found (e.g. ADVANCE-ID, located in Southeast Asia).

With these, we framed the themes for the 2024 funding calls.

**2024 FUNDING CALL THEMES**

**THERAPEUTICS FOR INFECTIONS CAUSED BY GRAM-NEGATIVE PATHOGENS**

- Required: direct-acting, small-molecule antibiotic
- Preferred: properties to deliver both IV and oral forms

**DIAGNOSTICS FOR NEONATAL SEPSIS**

- Target Indications: VAP/ VAP, cUTI (and associated bacteremias)
- Key Criteria:
  - Sample volumes, time-to-result, cost of goods, proof of concept data on clinical or continued samples

**PREVENTION FOR INVASIVE DISEASE**

- Required: novel approaches, with supportive preliminary data
- Preferred: non-vaccine, non-mAb
- Target Pathogens: S. aureus and E. coli

**NOVEL SAMPLE TYPES FOR DIAGNOSING LRTIs**

- Required: sample types other than BAL, ETA or sputum
- Preferred: alternative sample types with demonstration of detection of at least one bacterial pathogen at a clinically-relevant threshold
2022-2023 Omnibus Funding Round Outcomes

CARB-X received applications from a worldwide search for the best projects on three themes:

1. **ORAL THERAPEUTICS**
   - Oral therapeutics are essential to treat infections globally.
   - Several factors drive the need for new oral therapeutics:
     - Vaccines for Neonatal Sepsis
     - Gonorrhea

2. **VACCINES FOR NEONATAL SEPSIS**
   - Neonates are 69 times more likely to die from sepsis than children in the 5+ age bracket.
   - Infections that cause neonatal sepsis are particularly burdensome in LMICs.
   - CARB-X requires neonatal sepsis vaccines to target top causative agents in LMICs where commercial indications would also be possible for HICs.

3. **GONORRHEA PRODUCTS**
   - Ceftriaxone is the only antibiotic left that can effectively treat drug-resistant strains of gonorrhea.
   - CARB-X requested all gonorrhea products—vaccines, rapid diagnostics and oral therapeutics—to address drug-resistant strains with a focus on thinly-covered but important pathogens and syndromes.

CARB-X received 237 expressions of interest.

Here’s how the applications break down by theme and stage:

- **ORAL THERAPEUTICS**
  - 185 unique applicants
  - 125 applied to CARB-X for the first time

- **VACCINES FOR NEONATAL SEPSIS**
  - 35 expressions of interest

- **GONORRHEA PRODUCTS**
  - 90 expressions of interest

Demographics

Carb-X received applications from 185 unique applicants—from small to large companies and non-profit organizations—based in countries around the world.

- 91% were academic, and micro to medium and only
- 9% were large.

Trends

**Rapid diagnostics expanded during the COVID-19 pandemic.**

Developers built rapid tests to detect the SARS-CoV-2 virus. This resulted in a significant increase in diagnostic products in use by customers, near point-of-care diagnostics, and fully established commercial and reporting infrastructures. As the pandemic winds down, product developers are poised to capitalize on their investments by embracing new sample types and pathogens, including N. gonorrhoeae.

**Half of the therapeutics applicants were in the hit-to-lead stage.**

This is consistent with the dearth of oral therapeutics in the clinical and preclinical pipelines, and the barriers that product developers face as they attempt to advance oral therapeutics to patients. CARB-X aims to help these programs advance to the clinical stage and replenish the pipeline with new oral therapeutics.

CARB-X received 35 expressions of interest from the vaccine community, who understand that there is a need for targeting pathogens of interest.

In 2021, the World Health Organization reviewed the pipeline of bacterial vaccines. Few are in clinical development for pathogens of interest. These include:

- 1 for K. pneumoniae
- 5 for Extraintestinal Pathogenic E. coli
- 11 for S. aureus
- 0 for A. baumannii
- 1 for N. gonorrhoeae

Historically, the pathogen S. aureus has posed challenges for vaccine developers, which has resulted in a high number of failed attempts. This is why CARB-X sought new approaches to develop an effective vaccine that can target S. aureus in our 2024 call.
The research team, led by Professor Christopher McDevitt, PhD, Laboratory Head at the Doherty Institute, investigates how pathogenic bacteria interact with the host environment and the specific role played by metal ions. Pictured from left to right: Dr. Aimee Tan, Dr. Jonathan Wilksch, Prof. Christopher McDevitt, Dr. Blas Cunningham, and Dr. Stephanie Neville.

**CARB-X Portfolio Acceleration Tools**

CARB-X is supporting several projects, called Portfolio Acceleration Tools (PATs), that aim to bridge gaps in the translation of novel antimicrobials to approved therapies. Below we highlight advancement of our lung model PAT this year.

### Animal lung model PAT

**HEALTH IMPACT:**

Lower-respiratory-tract infections remain the world’s most deadly communicable disease.

![CARB-X Portfolio Acceleration Tools](image)

**PURPOSE OF THE PAT:**

Preclinical data from lung infection animal models do not always translate to the clinic. For example, tigecycline is an antibiotic that showed efficacy in mice, but not for human lung infections. CARB-X is collaborating with partners to advance a standard animal lung model for product developers, so their research will have translational value. This could help save time and money, while moving antibacterial products more quickly to patients. The PAT research will be published in open-access journals, so any team around the world could use the model and compare results across laboratories.

**DESIGN:**

CARB-X began with the IMI Antimicrobial Resistance (AMR) Accelerator standardized animal model, currently assessed across different laboratories, to determine whether clinical exposures are effective in this animal model. The Center for Anti-Infective Research and Development (CAIRD) tested humanized exposures of antibiotics that target lung infections and those that do not, to provide positive and negative controls. Several strains of *Klebsiella pneumoniae* and *Pseudomonas aeruginosa* were tested, since these are two prominent bacteria that cause lung infections.

**STATUS:**

During 2023, humanized exposures were tested in the animal model and analyzed for two antibiotics, tigecycline (negative control) and levofloxacin (positive control). The results supporting the validation of the animal lung model are anticipated to be published in 2024 and three additional, clinically-used antibiotics will be studied to provide a fullscale model. All bacterial strains will become available to researchers through the Leibniz Institute DSMZ-German Collection of Microorganisms and Cell Cultures GmbH depository in Germany.
How CARB-X Benefits Vulnerable Individuals in LMICs

STEWARDSHIP AND ACCESS PLANS PUBLISHED

CARB-X’s goal is to accelerate antibacterial product development from concept through development. To ensure products are appropriately stewarded and accessible globally, CARB-X contractually requires all product developers in our portfolio to develop Stewardship and Access Plans. This year, two product developers published their Plans:

- BioMérieux’s VITEK® REVEAL™ Rapid AST System is an automated in vitro diagnostic system for quantitative and qualitative phenotypic antimicrobial susceptibility testing directly from positive blood culture.
- The T2Resistance® Panel is a direct-from-blood diagnostic designed to detect genetic markers associated with antibiotic-resistant gram-negative and gram-positive bacterial bloodstream infections.

CARB-X will continue to publish product developers’ Stewardship and Access Plans as their products progress.

IN VITRO DIAGNOSTIC PRODUCT DEVELOPMENT SERIES

We have funded three Indian companies, one of them a diagnostic program. That experience prompted a six-part video series to help diagnostic companies from lower-resource settings to move forward with CARB-X. In previous funding rounds, CARB-X noticed a trend in how diagnostic companies, one of them a diagnostic company, many struggled to articulate how they would translate them into meaningful products.

In April 2023, CARB-X developed a webinar series with FIND and C-CAMP to coach product developers from LMICs how to move their in vitro diagnostics (IVD) from concept through development.

The series aimed to help product developers:
- strengthen their business plans,
- improve their applications to become more competitive for CARB-X funding,
- increase access to diagnostics in LMICs.

The free six-part video series is now available on CARB-X.org, in February 2023, C-CAMP hosted an in-person training session in India and Indonesia. CARB-X added modules on regulatory, procurement, and other advanced steps.

SIX-PART VIDEO SERIES

1. Introduction to IVD Product Development
2. Product Development Process
3. Design Control
4. Quality Management System
5. Good Lab Practices
6. Why the Fundamentals Matter

Scan to view the free six-part video series.

Q&A

Diane MacDonald was CARB-X Chief Operating Officer from 2018-2023 and Maria Uria-Nickelsen, an Alliance Director within the CARB-X Research & Development Team from 2019-2023. Both retired in 2023. Before they departed, we asked them to describe the most significant attributes of CARB-X, as it evolved over their tenures. Here’s what they had to say.

How is CARB-X developing new tools to advance products and global partnerships?

- Diane MacDonald: CARB-X pursues Portfolio Acceleration Tools that impact product developers in the portfolio. CARB-X uses strategic reviews to debate science and strategy to push the envelope of innovation. Conditional milestones and units of work are created to minimize risk and improve study designs, and funding round decisions are thoroughly evaluated to enable selection of programs across a risk-value spectrum.

- Maria Uria-Nickelsen: The CARB-X R&D Team has decades of experience leading projects in different settings. Our Scientific Advisory Boards are built with expertise across all disciplines. The Clinical Advisory Board selects the best plan and design based on innovative approaches and deep experience.

What does the integration of deep antimicrobial expertise across disciplines and stages of development coupled with non-scientific capabilities to support the portfolio look like at CARB-X?

- Maria Uria-Nickelsen: The CARB-X R&D Team has decades of experience leading projects in different settings. Our Scientific Advisory Boards are built with expertise across all disciplines. The Clinical Advisory Board selects the best plan and design based on innovative approaches and deep experience.

- Diane MacDonald: CARB-X has staff in finance, research compliance, legal, project management, and communications that all provide direct assistance to product developers. There are standard operating procedures and tools developed to ensure CARB-X funding requirements are understood. Information platforms allow for the exchange of information between product developers and the CARB-X team in a secure, user-friendly manner.

How has CARB-X developed the most innovative portfolio across 3 different pillars and become the most effective global partnership to leverage funding and support?

- Maria Uria-Nickelsen: CARB-X has developed the fund of bacteria, phage, antivirulence compounds, and antibiotics in the therapies pillar. Within the preventative pillar, we have vaccines, bacteriophages, and live-bio-therapeutic products, as well as genetic-based diagnostics in the diagnostics pillar of the CARB-X portfolio.

- Diane MacDonald: In terms of global partnerships, CARB-X developed a consolidation of separate funding sources in a unified partnership. CARB-X leverages funding through jointly agreed strategic objectives and a uniform set of contractual terms. CARB-X has matured as a lean organization, leveraging funds invested to ultimately see results in patients.
CARB-X is a global non-profit partnership that accelerates antibacterial research and development. CARB-X awards non-dilutive funding and provides scientific, regulatory and business expertise to support early-stage development of products that aim to prevent, diagnose and treat the most dangerous drug-resistant bacterial infections.

SUPPORT SINCE 2016

- Annual Report
- Financial Data
- Cumulative as of 12/31/2023

Pending awards to product developers $30.1M
Technical experts provided to product developers* $33.1M
NIAID in-kind services to product developers $50.0M
CARB-X personnel and internal operations $14.3M
Boston University services $21.1M
Awards to product developers $440.4M

94% of funding goes to product developers via direct awards or technical and in-kind support.

*Includes Global Accelerator Network, Portfolio Acceleration Tools, Advisory Boards, and external and in-house R&D technical experts

HOSTED BY:

CARB-X
Boston University School of Law
771 Commonwealth Avenue
Boston, MA, USA 02215